Product Class

1622902-68-4

Q: What is the N-{trans-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide?

N-{trans-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide is , while it's Molecular Formula is C 14 H 21 N 5 O 2 S.

Q: What is the CAS number for N-{trans-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide?

The CAS number of N-{trans-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide is 1622902-68-4.

Product Name：Abrocitinib
Molecular Formula：C₁₄H₂₁N₅O₂S
Purity：99%
Molecular Weight：323.419

Inquiry

Product Details:

CasNo： 1622902-68-4

Molecular Formula： C₁₄H₂₁N₅O₂S

Quality Factory Supply Abrocitinib ,High Purity 1622902-68-4 Safe Shipping

Molecular Formula:C₁₄H₂₁N₅O₂S

Molecular Weight:323.419
Density:1.36±0.1 g/cm3(Predicted)

Abrocitinib(Cas 1622902-68-4) Usage

Description

Abrocitinib, marketed under the brand name Cibinqo, is a prescription medication designed to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 and older. As a Janus kinase (JAK) inhibitor, it functions by blocking the activity of JAK1, a key player in the immune response. This medication is prescribed when other treatments have proven ineffective or are not well-tolerated, providing an option for patients with inadequately controlled atopic dermatitis.

Uses

Developed by Pfizer, Abrocitinib has undergone successful clinical trials demonstrating both efficacy and safety in both adult and pediatric populations. It has shown effectiveness in cases where other medications have fallen short, establishing its role as a viable alternative for individuals who cannot tolerate or adequately respond to other treatments. Notably, Abrocitinib's immunosuppressive effects extend to reducing the impact of adenovirus types 4 and 7 live, oral. As a JAK1 selective inhibitor, Abrocitinib is one of the pioneering medications in the JAK inhibitor category evaluated for treating atopic dermatitis. Clinical trials have revealed its positive risk-benefit profile, showcasing its potential as a therapeutic option with both advantages and limitations. This oral medication represents a valuable addition to the treatment arsenal for moderate-to-severe atopic dermatitis, providing relief for patients who may not respond well to or tolerate other available therapies.

1622902-68-4 Relevant articles

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

Vazquez, Michael L.,Kaila, Neelu,Strohbach, Joseph W.,Trzupek, John D.,Brown, Matthew F.,Flanagan, Mark E.,Mitton-Fry, Mark J.,Johnson, Timothy A.,Tenbrink, Ruth E.,Arnold, Eric P.,Basak, Arindrajit,Heasley, Steven E.,Kwon, Soojin,Langille, Jonathan,Parikh, Mihir D.,Griffin, Sarah H.,Casavant, Jeffrey M.,Duclos, Brian A.,Fenwick, Ashley E.,Harris, Thomas M.,Han, Seungil,Caspers, Nicole,Dowty, Martin E.,Yang, Xin,Banker, Mary Ellen,Hegen, Martin,Symanowicz, Peter T.,Li, Li,Wang, Lu,Lin, Tsung H.,Jussif, Jason,Clark, James D.,Telliez, Jean-Baptiste,Robinson, Ralph P.,Unwalla, Ray

, p. 1130 - 1152 (2018)

Janus kinases (JAKs) are intracellular t...

Development of a Nitrene-Type Rearrangement for the Commercial Route of the JAK1 Inhibitor Abrocitinib

Connor, Christina G.,Deforest, Jacob C.,Dietrich, Phil,Do, Nga M.,Doyle, Kevin M.,Eisenbeis, Shane,Greenberg, Elizabeth,Griffin, Sarah H.,Jones, Brian P.,Jones, Kris N.,Karmilowicz, Michael,Kumar, Rajesh,Lewis, Chad A.,McInturff, Emma L.,McWilliams, J. Christopher,Mehta, Ruchi,Nguyen, Bao D.,Rane, Anil M.,Samas, Brian,Sitter, Barbara J.,Ward, Howard W.,Webster, Mark E.

, p. 608 - 615 (2020/10/09)

The development of a commercial route to...

TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF

-

Paragraph 00299, (2020/05/28)

Provided are novel class of therapeutics...

METHOD FOR PRODUCING PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND INTERMEDIATE AND METHOD FOR USING THE SAME

-

Paragraph 0104; 0106-0107, (2020/03/10)

PROBLEM TO BE SOLVED: To provide a metho...

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Novin Nezamololama, BSc, MSc,1 Keira Fieldhouse, BSc,1,2 Kristy Metzger, BSc,1,2 and Melinda Gooderham, MD, MSc, FRCPCcorresponding author1,3,4

Drugs Context. 2020; 9: 2020-8-5.

This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of AD. The safety and efficacy of JAK inhibitors for the treatment of AD are emerging in the literature.

1622902-68-4 Process route

: N-(cis-3-(methyl(7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide

: 1622902-68-4
PF-04965842

Conditions

Conditions	Yield
With lithium hydroxide monohydrate; water; In isopropyl alcohol; at 60 ℃; for 13h;	35%
With sodium hydroxide; In 2-methyltetrahydrofuran; water; for 1h; Inert atmosphere; Reflux;	56.2 g
With sodium hydroxide; In water; at 70 ℃; for 4h;	5.39 g

: 10147-36-1
n-propanesulfonyl chloride

: (1s,3s)-N₁-methyl-N₁-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclobutane-1,3-diamine phosphoric acid

: 1622902-68-4
PF-04965842